Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

NCT07060989 is registered in ClinicalTrials.gov with Nutshell Therapeutics (Shanghai) Co., LTD. as lead sponsor.

NCT NCT07060989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07060989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
Lead sponsor
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 4, 2025
Completion date
December 31, 2029
Enrollment
220 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors